TNFSF10 and breast carcinoma: Low levels of surface DR5 are known to contribute to TRAIL-resistance in breast cancer [13] and we hypothesized that ONC201 treatment of TRAIL-resistant non-TNBC cells was not leading to upregulation of the receptor.